STF-logo-1

We use cookies to provide you a better experience. By continuing to use this website, you consent to the use of cookies in accordance with our Cookie Policy.

Healthcare

Delivering solutions in M&A, Capital Raising, and Restructuring

Healthcare Investment Banking Group

Finding financial solutions across every sector of the healthcare ecosystem.

A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.

Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco, London, Toronto, and Montreal, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.

Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.

Read Our Latest Thoughts on Investment Banking in the Healthcare Sector

Learn More

Areas of Expertise

Notable Transactions

Image
$ 175,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2025

Image
$ 202,000,000
Joint Bookrunning Manager

Initial Public Offering

Medtech

Mar 2025

Image
$ 150,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Feb 2025

Image
Advisor to Buyer

Mergers & Acquisitions

Healthcare

Feb 2025

Image
$ 219,200,000
Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2025

Image
$ 75,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2025

Image
Advisor to Pieris

Mergers & Acquisitions

HealthTech

Dec 2024

Image
$ 50,000,000
Joint Bookrunner

Registered Direct

Biopharma

Dec 2024

Image
$ 257,600,000
Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2024

Image
Advisor to Seller

Mergers & Acquisitions

HealthTech

Dec 2024

Image
$ 402,500,000
Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2024

Image
$ 60,000,000
Joint Bookrunner & Joint Placement Agent

Registered Direct & PIPE

Biopharma

Nov 2024

Image
$ 310,000,000
Advisor to Seller

Mergers & Acquisitions

Medtech, Healthcare

Jul 2024

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare, Biopharma

Aug 2024

Image
Sole Financial Advisor

Mergers & Acquisitions

Healthcare Services

Oct 2024

Image
Advisor to Buyer

Mergers & Acquisitions

Biopharma

Oct 2024

Image
$ 575,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2024

Image
$ 187,680,000
Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2024

Image
$ 362,250,000
Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2024

Image
$ 200,536,320
Joint Placement Agent

PIPE

Biopharma

Sep 2024

Image
$ 258,750,000
Joint Bookrunning Manager

Follow-on Offering

Biopharma

Sep 2024

Image
$ 200,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2024

Image
$ 258,750,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Aug 2024

Image
$ 130,000,000
Joint Bookrunner

Registered Direct

Biopharma

Aug 2024

Image
$ 33,900,000
Sole Bookrunner

Follow-on Offering

Biopharma

Aug 2024

Image
$ 100,000,000
Lead Financial Advisor

Convertible Notes & Senior Secured Term Loan

Medtech

Aug 2024

Image
$ 128,000,000
Financial Advisor

SPAC Merger

Medtech

Jul 2024

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare

Jul 2024

Image
Advisor to Buyer

Mergers & Acquisitions

HealthTech

Jul 2024

Image
Advisor to Seller

Mergers & Acquisitions

Biopharma

Jul 2024

Image
€ 52,500,000
Exclusive Debt Advisor

Secured Credit Facility

Healthcare

Jun 2024

Image
$ 174,400,000
Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2024

Image
$ 60,000,000
Joint Bookrunner

Registered Direct

Biopharma

May 2024

Image
$ 374,325,000
Joint Bookrunner

Follow-on Offering

Biopharma

May 2024

Image
$ 75,000,000
Sole Bookrunner

Registered Direct

Biopharma

May 2024

Image
$ 121,600,000
Advisor to Seller

Has Sold Assets to

Medtech

Apr 2024

Image
$ 94,300,000
Advisor to Sientra

Aggregate Indebtedness

Medtech

Apr 2024

Image
$ 280,000,000
Joint Placement Agent

PIPE

Biopharma

Apr 2024

Image
$ 201,250,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2024

Image
Advisor to Seller

Mergers & Acquisitions

Biopharma

Apr 2024

Image
$ 110,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

Apr 2024

Image
Financial Advisor

Mergers & Acquisitions

Biopharma

Mar 2024

Image
C$ 23,011,788
Joint Bookrunner

Follow-on Offering

Healthcare & Special Situations

Mar 2024

Image
$ 240,100,310
Joint Bookrunner

Registered Direct

Biopharma

Mar 2024

Image
$ 150,000,000
Joint Bookrunner

Registered Direct

Biopharma

Mar 2024

Image
$ 180,000,000
Joint Placement Agent

PIPE

Biopharma

Mar 2024

Image
$ 482,999,902
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2024

Image
$ 140,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2024

Image
£ 31,000,000
Joint Bookrunner, Joint Corporate Broker, NOMAD

Follow-on Offering

Healthcare

Mar 2024

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Mar 2024

Image
$ 632,540,250
Joint Bookrunner

Follow-on Offering

Biopharma

Feb 2024

Image
$ 34,400,000
Advisor to Buyer

Mergers & Acquisitions

HealthTech

Feb 2024

Image
C$ 6,000,000

Follow-on Offering

Biopharma

Feb 2024

Image
$ 160,125,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Feb 2024

Image
$ 345,144,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2024

Image
$ 230,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2023

Image
$ 20,300,000
Left Bookrunner

Registered Direct

HealthTech

Dec 2023

Image
$ 180,000,000
Joint Placement Agent

PIPE

Biopharma

Dec 2023

Image
$ 100,000,000
Advisor to Buyer

Mergers & Acquisitions

Biopharma

Dec 2023

Image
Advisor to Seller

Mergers & Acquisitions

Biopharma

Nov 2023

Image
$ 300,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Nov 2023

Image
$ 245,000,000+
Advisor to Licensee

In-Licensing

Biopharma

Nov 2023

Image
Advisor to Seller

Mergers & Acquisitions

HealthTech

Nov 2023

Image
$ 111,536,216
Joint Bookrunner

Initial Public Offering

Biopharma

Nov 2023

Image
$ 150,150,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Oct 2023

Image
$ 517,500,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Oct 2023

Image
€ 154,430,010
Advisor to Seller

Mergers & Acquisitions

Medtech

Oct 2023

Image
$ 90,833,010
Advisor to Buyer

Mergers & Acquisitions

Biopharma

Oct 2023

Image
$ 100,000,000
Joint Bookrunner

Registered Direct

Biopharma

Oct 2023

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare

Sep 2023

Image
$ 250,070,000
Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2023

Image
$ 115,000,000
Joint Bookrunner

Confidentially marketed Follow-on Offering

Biopharma

Sep 2023

Image
$ 345,057,500
Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2023

Image
$ 130,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jul 2023

Image
£ 10,000,000
Joint Bookrunner

Equity Placing

Healthcare

Jul 2023

Image
$ 200,000,000
Investment Banker for Tricida

Chapter 11 Restructuring

Biopharma

Jun 2023

Image
$ 120,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jun 2023

Image
$ 137,200,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jun 2023

Image
$ 460,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2023

Image
$ 20,300,000
Sole Placement Agent and Nomad

PIPE

Healthcare

Feb 2023

Image
$ 220,800,000
Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2023

Image
$ 100,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Feb 2023

Image
$ 227,843,965
Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2023

Image
$ 120,000,000
Left Bookrunner

Convertible Notes

Medtech

Dec 2022

Image
$ 65,010,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2022

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare

Dec 2022

Image
$ 115,799,748
Joint Bookrunner & Joint Placement Agent

Registered Direct & PIPE

Biopharma

Dec 2022

Image
Advisor to Seller

Mergers & Acquisitions

Maritime Services, Healthcare Services

Dec 2022

Image
$ 300,375,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2022

Image
$ 64,000,000
Advisor to Seller

Mergers & Acquisitions

Tools & Diagnostics

Nov 2022

Image
$ 850,000,000
Financial and Capital Markets Advisor

Mergers & Acquisitions

Biopharma

Nov 2022

Image
£ 64,000,000
Sole Bookrunner, Sole Placement Agent, Sole Broker and Nomad

Convertible Bond & Follow-on Offering

Healthcare Services

Oct 2022

Image
Advisor to Seller

Mergers & Acquisitions

Biopharma

Sep 2018

Image
$ 125,000,000
Financial Advisor

Strategic Financing Agreement

Biopharma

Feb 2019

Image
$ 115,000,000
Joint Bookrunner

Follow-on Offering

Medtech

Oct 2022

Image
$ 58,079,577
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Sep 2022

Image
$ 124,800,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Sep 2022

Image
$ 260,000,000
Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Aug 2022

Image
$ 84,249,986
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Aug 2022

Image
$ 862,500,000
Lead Manager

Follow-on Offering

Biopharma

Aug 2022

Image
$ 143,893,750
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Aug 2022

Image
$ 55,300,000
Sole Bookrunner

Exchange of Convertible Notes

Medtech

Jul 2022

Image
$ 104,500,000
Sole Placement Agent

Senior Secured Term Loan

Medtech

Jul 2022

Image
$ 1,200,000,000
Advisor to Seller

Mergers & Acquisitions

Medtech

Jul 2022

Image
$ 250,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

HealthTech

Jun 2022

Image
£ 34,261,864
Joint Bookrunner

Follow-on Offering

Biopharma

May 2022

Image
$ 79,347,051
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2020

Image
C$ 34,511,565
Joint Bookrunner

Follow-on Offering

HealthTech

May 2022

Image
$ 108,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

May 2022

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare Services

May 2022

Image
$ 39,054,798
Advisor to Buyer

Mergers & Acquisitions

Medtech

Apr 2020

Image
$ 43,000,000
Lead Placement Agent

Private Placement

Biopharma

Nov 2021

Image
$ 40,000,000
Financial Advisor

Registered Direct

HealthTech

Mar 2022

Image
$ 200,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

Apr 2022

Image
$ 230,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2022

Image
€ 15,000,000
Joint Global Coordinator and Joint Bookrunner

Follow-on Offering

Healthcare

Apr 2022

Image
$ 30,000,000
Sole Financial Advisor and Sole Placement Agent

Convertible Bond and Equity Placing

Medtech

Mar 2022

Image
$ 75,000,000
Left Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2022

Image
$ 230,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2022

Image
$ 2,350,000,000
Joint Bookrunner

Senior Notes

HealthTech

Feb 2022

Image
$ 100,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jan 2022

Image
$ 98,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

Jan 2022

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Dec 2021

Image
$ 52,325,000
Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2021

Image
$ 172,500,000
Left Bookrunner

SPAC IPO

Biopharma

Nov 2021

Image
C$ 65,000,000
Co-Lead Manager

Convertible Notes

HealthTech

Nov 2021

Image
$ 80,500,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Nov 2021

Image
$ 100,800,000
Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Nov 2021

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Nov 2021

Image
$ 158,000,000
Capital Markets Advisor

Mergers & Acquisitions

HealthTech

Nov 2021

Image
$ 230,000,000
Joint Bookrunner

Initial Public Offering

Healthcare Services

Nov 2021

Image
$ 93,600,000
Joint Bookrunner

Initial Public Offering

Medtech

Oct 2021

Image
$ 150,750,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Oct 2021

Image
$ 74,865,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Oct 2021

Image
Advisor to Seller

Mergers & Acquisitions

Medtech

Oct 2021

Image
$ 345,000,000
Joint Bookrunner

Follow-on Offering

Medtech

Oct 2021

Image
C$ 7,004,400
Joint Bookrunner

Follow-on Offering

Healthcare & Special Situations

Oct 2021

Image
$ 70,900,000
Advisor to Buyer

Mergers & Acquisitions

Medtech

Oct 2021

Image
$ 13,200,000
Joint Bookrunner

Follow-on Offering

Healthcare Services

Sep 2021

Image
Advisor to Buyer

Mergers & Acquisitions

Medtech

Sep 2021

Image
$ 1,000,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2021

Image
$ 651,000,000
Capital Markets Advisor

SPAC Merger

Tools & Diagnostics

Sep 2021

Image
$ 181,500,000
Advisor to Seller

Mergers & Acquisitions

Biopharma

Jul 2021

Image
$ 212,000,000
Capital Markets Advisor

SPAC Merger & PIPE

Biopharma

Aug 2021

Image
$ 174,560,000
Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2021

Image
$ 180,132,080
Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Jul 2021

Image
$ 84,333,337
Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2021

Image
$ 80,000,000
Left Bookrunner

Follow-on Offering

Entertainment

Jun 2021

Image
$ 97,807,500
Joint Bookrunner

Initial Public Offering (U.S. Nasdaq)

Medtech

Jul 2021

Image
$ 62,675,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Jul 2021

Image
$ 100,190,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jul 2021

Image
Advisor to Buyer

Mergers & Acquisitions

Biopharma

Aug 2021

Image
$ 355,810,000
Joint Bookrunner

Initial Public Offering

Biopharma

Aug 2021

Image
£ 17,000,000
Sole Global Coordinator, Joint Bookrunner & Nomad

Initial Public Offering

HealthTech

Jul 2021

Image
Advisor to Seller

Mergers & Acquisitions

Biopharma

Jul 2021

Image
$ 350,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jul 2021

Image
$ 160,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2021

Image
$ 230,000,000
Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Jul 2021

Image
$ 160,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2021

Image
Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Jun 2021

Image
Capital Markets Advisor

SPAC Merger & PIPE

Biopharma

Feb 2021

Image
$ 55,000,000
Joint Placement Agent

PIPE

Biopharma

Mar 2021

Image
£ 40,000,000
Sole Placement Agent

PIPE

Biopharma

Feb 2021

Image
$ 2,200,000,000
Co-Manager

Senior Notes

Healthcare Services

Feb 2021

Image
$ 366,000,000
Co-Manager

Follow-on Offering

Medtech

Apr 2021

Image
$ 90,000,000
Advisor to Squadron

Has Invested in

Medtech

Mar 2021

Image
$ 138,250,000
Sole Bookrunner

Convertible Notes

Medtech

Mar 2021

Image
$ 42,000,000
Sole Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Feb 2021

Image
$ 287,500,000
Joint Bookrunner

Follow-on Offering

Biopharma

Apr 2021

Image
$ 160,425,000
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2021

Image
$ 98,325,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2021

Image
$ 100,912,500
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Apr 2021

Image
$ 646,875,000
Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Apr 2021

Image
$ 103,500,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

Image
$ 50,652,000
Left Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

Image
$ 550,000,000
Joint Bookrunner

Convertible Senior Notes

Biopharma

Apr 2021

Image
$ 30,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

Image
$ 48,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2021

Image
$ 56,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

Image
$ 218,500,000
Joint Bookrunner

Initial Public Offering

Biopharma

Mar 2021

Image
$ 115,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

HealthTech

Mar 2021

Image
$ 60,000,000
Joint Bookrunner

Follow-on Offering

HealthTech

Feb 2021

Image
$ 222,250,000
Joint Bookrunner

Follow-on Offering

HealthTech

Feb 2021

Image
$ 150,000,000
Joint Bookrunner

Follow-on Offering

HealthTech

Feb 2021

Image
$ 203,439,942
Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2021

Image
$ 264,500,000
Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2021

Image
$ 117,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2021

Image
$ 555,450,000
Joint Bookrunner

Initial Public Offering

Biopharma

Dec 2020

Image
$ 103,500,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2021

Image
$ 129,375,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jan 2021

Image
$ 70,000,000
Joint Placement Agent

Private Placement

HealthTech

Feb 2021

Image
$ 74,500,000
Left Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Feb 2021

Image
$ 277,725,000
Joint Bookrunner

Initial Public Offering

Biopharma

Dec 2020

Image
$ 264,000,000
Joint Bookrunner

Follow-on Offering

Healthcare Services

Jan 2021

Image
$ 168,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2021

Image
$ 200,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2020

Image
$ 345,080,500
Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2020

Image
$ 312,225,000
Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Dec 2020

Image
$ 750,000,000
Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Dec 2020

Image
$ 81,176,464
Joint Bookrunner

Initial Public Offering

Biopharma

Nov 2020

Image
$ 149,500,000
Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Dec 2020

Image
$ 104,796,260
Left Bookrunner

Initial Public Offering

Medtech

Oct 2020

Image
$ 1,898,938,296
Joint Financial Advisor

Mergers & Acquisitions

Biopharma

Oct 2020

Image
$ 2,128,500,000
Lead Manager

Initial Public Offering

Medtech

Oct 2020

Image
$ 1,863,000,000
Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Nov 2020

Image
$ 277,761,104
Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2020

Image
$ 267,696,966
Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2020

Image
$ 345,000,000
Lead Manager

Initial Public Offering

Medtech

Oct 2020

Image
$ 120,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jul 2020

Image
$ 963,470,000
Joint Bookrunner

Follow-on Offering

Biopharma

Aug 2020

Image
$ 140,000,000
Advisor to Seller

Mergers & Acquisitions

Biopharma

Aug 2020

Image
$ 200,000,000
Joint Bookrunner

Convertible Notes

Biopharma

Sep 2020

Image
$ 445,000,000
Financial Advisor

PIPE

Biopharma

Jul 2020

Image
$ 209,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2020

Image
$ 80,000,000
Lead Placement Agent

PIPE

Biopharma

Jul 2020

Image
$ 135,000,000
Advisor to Buyer

Mergers & Acquisitions

Biopharma

Jul 2020

Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.

Team

Team

Mark Dempster

Co-Head Healthcare

New York

Team

Declan Quirke

Co-Head Healthcare

New York

Team

Seth Rubin

Head of Global Equity Capital Markets

San Francisco

Team

Alena Antigua

Managing Director

Chicago

Team

Tom Babich

Managing Director

New York

Team

Tom Bird

Managing Director

New York

Team

Sean Cessna

Managing Director

San Francisco

Team

Melissa Chan

Managing Director

New York

Team

Ken Clausman

Managing Director

New York

Team

Kelly Curtin

Managing Director

London

Team

Samira Essebiyea

Managing Director

London

Team

Benj Garrett

Managing Director

New York

Team

James Hesburgh

Managing Director

New York

Team

Charles Hoare

Managing Director, Co-Head of European Healthcare Investment Banking

London

Team

Neal Karnovsky

Managing Director, Healthcare M&A

New York

Team

Brian Kim

Managing Director

New York

Team

Susan Kirtland

Managing Director

New York

Team

Adam Kohn

Managing Director

New York

Team

Patrick Krause

Managing Director

San Francisco

Team

Nitin Lath

Managing Director

Team

Allen Lefkowitz

Managing Director

New York

Team

Stephanie Léouzon

Managing Director, Vice Chair of European Healthcare Investment Banking

London

Team

Jie Liu

Managing Director

New York

Team

William McGrath

Managing Director

New York

Team

Nicholas Moore

Managing Director, Co-Head of European Healthcare Investment Banking

London

Team

Klaus Nestler

Managing Director

Frankfurt

Team

Tim Opler

Managing Director

New York

Team

Nicholas Oust

Managing Director

San Francisco

Team

Alan Selby

Managing Director

London

Team

Ping Shek

Managing Director

London

Team

Harrison Callaway

Director

New York

Team

Nick Hiller

Director

New York

Team

Kylor Hua

Director

New York

Team

Ben Maddison

Managing Director

London

Team

Gwendolyn Melnyk

Director

New York

Team

Jerome Raymond

Director

London

Team

Charles Simon

Director

New York

Team

Ahmed Soibah

Director

Paris

Team

Hetal Vora

Director

Team

Steven Zhou

Director

San Francisco

About Us Stifel Institutional Stifel Sustainability Practices
Capabilities Investment Banking Equities Equity Research Fixed Income Capital Markets Public Finance Serving Business Leaders
Global Coverage Overview Europe & UK Canada Asia Israel Latin America
Insights & Perspectives Thought Leadership Stifel in the News Stifel Investor Insights Stifel IRIS
Careers Experienced Professionals Campus Careers & Entry Level Opportunities
Disclosures Important Disclosures Your Privacy Form CRS FINRA BrokerCheck
Connect with Stifel Client Access Stifel Wealth Tracker
STF-footer-logo

In the United States, this site is published in the United States for U.S. residents only. The information on this web site is not an offer to sell or a solicitation of an offer to buy any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase, or sale may not lawfully be made. Stifel Financial Advisors may only conduct business with residents of the states in which they are properly registered. References to Stifel herein may apply to parent company Stifel Financial Corp. or any of its wholly owned subsidiaries, including Stifel, Nicolaus & Company, Incorporated, Member NYSE, FINRA, and SIPC. Stifel Nicolaus Europe Limited is authorised and regulated by the Financial Conduct Authority.

Copyright © 2025 Stifel Financial Corp. All rights reserved.